The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis

Abstract

Background Osteoporosis is a metabolic bone disease. Bisphosphonate (BP) and eldecalcitol (ELD) are two clinical first-line drugs for osteoporosis patients. However, the effect of ELD + BP vs. BP alone on osteoporosis treatment is still unclear. The present meta-analysis was conducted to evaluate the different therapeutic effect of BP + ELD vs. BP alone in osteoporosis treatment. Methods Eligible documents that selected from online databases including PubMed, Embase, and Cochrane Library were included in this study (updated to March 3, 2020). The quality assessment of the included studies was based on the guidelines of Cochrane. Meta-analysis was performed according to criteria such as intervention plan and outcome. The indicators including bone mineral density (BMD) in all enrolled studies were included in the current analysis. Pooled odds ratios (ORs) and weighted mean differences (WMDs) with 95% confidence intervals (CI) were calculated using fixed- or random-effects models. Then, heterogeneity analysis was performed based on Cochran’s Q test and I2 statistics. Results A total of 4 studies (456 cases) with high quality were enrolled in this study. The effect of ELD + BP was superior to BP alone based on indicators including femoral neck BMD (FN-BMD) and total hip BMD (TH-BMD) in patients with followed up ≤ 6 months. Moreover, the effect of ELD + BP was superior to BP alone based on lumbar spine BMD (LS-BMD) in patients with 12 months followed up. Conclusion Therapeutic effect of ELD + BP was superior to BP alone in osteoporotic patients based on the influence of BMD.

Efficacy and Safety of Eldecalcitol for Osteoporosis: A Meta-Analysis of Randomized Controlled Trials

“…performed a meta-analysis of four studies and found that ED-71 plus bisphosphonate was associated with high FN-BMD and hip BMD after 6 months compared with bisphosphonate alone. Moreover, these effects were not observed after 12 months, while ED-71 plus bisphosphonate was associated with high lumbar spine BMD after 12 months compared with bisphosphonate alone ( 30 ). However, the analysis of this study was based on two RCTs and two observational studies, and the pooled results might be affected by uncontrolled biases.…”

Eldecalcitol prevents muscle loss by suppressing PI3K/AKT/FOXOs pathway in orchiectomized mice

“…Sarcopenia is characterized by an age-related loss of skeletal muscle mass and strength, with decline in hormone levels and number of neuromuscular junctions, increased inflammation, and decline in the physical activity or inadequate nutrition ( Santilli et al, 2014 ). Osteoporosis is a progressive bone disease that causes weak and brittle bones, a decrease in bone mass and density leading to debilitating fragility fractures ( Zeng et al, 2019 ; Zheng and Luo, 2020 ). Both these diseases also reduce the quality of life and mobility, resulting in significant morbidity and mortality ( Noguchi et al, 2013 ).…”

“…Osteoporosis causes an estimated 8.9 million fractures worldwide annually in 20%–25% of men ( Zheng and Luo, 2020 ; The Lancet Diabetes and Endocrinology, 2021 ). It is estimated that China alone has 13% prevalence of osteoporosis, and the annual number of osteoporosis-associated fractures is predicted to grow by 4.8 million by 2035 ( Zeng et al, 2019 ).…”